Case Report: Allogenic Wharton's jelly mesenchymal stem cell and exosome therapy are safe and effective for diabetic kidney failure

Abstract

Diabetes typically leads to repercussions such as chronic kidney disease (CKD), a worldwide health problem. Dialysis is typical for severe renal function loss (eGFR 15), but complications continue to exist. Chronic dialysis shortens life expectancy, and the wait for a transplant can be long, resulting in significant mortality. Human umbilical cord-derived Wharton’s jelly mesenchymal stem cells (hWJ-MSCs) have shown potential in regenerative healthcare for kidney repair, with unique capacities in restoring function and repairing damaged kidneys in animal models of chronic renal failure. The need to advance alternative medicines, such as regenerative medicine, in addressing crucial concerns in CKD care is stressed. We present the first case report in humans of a 70-year-old male with stage V chronic kidney disease caused by type 2 diabetes mellitus who received allogenic hWJ-MSCs and exosomes. The procedure includes the intravenous infusion of 100 million stem cells and 100 billion exosomes, which proved to be safe with no side effects. The renal profile improved significantly between the first and fourth months after infusion, according to assessments comprising lab results and the KDQOL-36TM questionnaire. Human umbilical cord Wharton’s jelly-derived mesenchymal stem cell implantations proved safe and effective in treating CKD.